Navigation Links
New role for Vascular Endothelial Growth Factor in regulating skin cancer stem cells
Date:10/19/2011

Skin squamous cell carcinomas are amongst the most frequent cancers in humans. Recent studies suggest that skin squamous cell carcinoma, like many other human cancers, contain particular cancer cells, known as cancer stem cells, that present increased self-renewal potential that sustain tumor growth. Little is known about the mechanisms that regulate cancer stem cell functions.

High level of VEGF expression in skin cancer stem cells

To dissect the mechanisms that regulate cancer stem cells, the researchers determined which genes are preferentially expressed by cancer stem cell of skin tumors. They found that VEGF, a molecule known to regulate the formation of new vessels, is expressed at high level by skin cancer stem cells, which are located in close contact to the blood vessels. Administration of an antibody that decreases new blood vessel formation to mice presenting skin tumors results in a reduction of the pool of cancer stem cells leading to a reduction of the tumor size, demonstrating that vascular cells regulates skin cancer stem cell functions.

To determine whether VEGF secretion by cancer stem cells directly regulates the function of cancer stem cells, the authors genetically removed VEGF specifically in tumour cells, and found that upon VEGF ablation, skin cancer stem cells are rapidly lost due to a defect in their renewal properties, leading to tumour regression.

"It was extremely exciting to see the complete disappearance of these tumors only two weeks after the treatment" said Benjamin Beck, the first author of the Nature paper.

Critical role for Neuropilin 1, a VEGF receptor

The authors also found that Neuropilin 1, a VEGF receptor, is also highly expressed by skin cancer stem cells, and showed that Neuropilin 1 expression by cancer stem cells is critical to promote cancer stem cell renewal and tumour growth. In addition, the authors found that Neuropilin 1 is also essential for tumour formation, demonstrating the critical role of Neuropilin 1 during both cancer initiation and tumor growth.

Altogether this new study provides novel and important insights into the mechanisms by which VEGF controls tumour growth. VEGF signalling in endothelial cells is critical to sustain the formation of the vascular niche, promoting indirectly the renewal of skin cancer stem cells. VEGF secretion by cancer stem cells acts also directly on cancer stem cells by a Neuropilin 1 dependent mechanism to promote cancer stem cell renewal and tumor growth.

"Anti-VEGF therapies are currently used to treat cancers. These new results have important implications for the prevention and treatment of different epithelial cancers, as new therapies blocking VEGF and/or Neuropilin 1 functions in cancer cells may be more effective for the treatment of certain cancers compared to the therapeutic strategies blocking VEGF function only in endothelial cells" said Cdric Blanpain, the senior and corresponding author of the Nature paper.

Collaboration between Flemish and Walloon academic institutions (VIB, K.U.Leuven, UGent, ULB, FNRS, Welbio

This work is also a great example of a very effective collaboration between Walloon (ULB, FNRS, Welbio) and Flemish Universities (VIB-K.U.Leuven and VIB-UGhent).

"This collaboration nicely illustrates the great strength of a national collaboration mixing the different and unique expertises of the different Belgian groups with the same and unique goal of better understanding and treating cancer." said Peter Carmeliet (VIB-K.U.Leuven), co-author of the paper.

In conclusion, this new study, published in the online early edition of Nature, identifies a dual role for VEGF in regulating skin cancer stem cells and tumor progression.


'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
32-477-697-668
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology technology :

1. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
2. Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study
3. Creating a Road Map for Successful Cardiovascular New Product Launch
4. Pediatrics Study Finds Children Taking ADHD Medications Did Not Suffer More Serious Heart Problems or Cardiovascular-related Death
5. SpectraCell Now Offers LPP™ Cardiovascular Testing in New York
6. Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
7. New CDC Guidelines for Prevention of Intravascular Catheter-Associated Infections Designate Chlorhexidine Gluconate-Impregnated Sponge as a Category 1B Recommendation Exclusively Based on Evidence Related to BIOPATCH® Protective Disk With CHG
8. Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device
9. Study Shows Cardiovascular Deaths in Europe Could Be Prevented
10. Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology
11. Stryker Announces Definitive Agreement to Acquire the Neurovascular Division of Boston Scientific for $1.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):